- Home
- HFRO vs ALDX Comparison
HFRO vs ALDX Comparison
Compare HFRO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- ALDX
- Stock Information
- Founded
- HFRO 2000
- ALDX 2004
- Country
- HFRO United States
- ALDX United States
- Employees
- HFRO N/A
- ALDX N/A
- Industry
- HFRO Finance/Investors Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- ALDX Health Care
- Exchange
- HFRO Nasdaq
- ALDX Nasdaq
- Market Cap
- HFRO 352.4M
- ALDX 304.9M
- IPO Year
- HFRO N/A
- ALDX 2014
- Fundamental
- Price
- HFRO $5.78
- ALDX $5.52
- Analyst Decision
- HFRO
- ALDX Strong Buy
- Analyst Count
- HFRO 0
- ALDX 2
- Target Price
- HFRO N/A
- ALDX $10.00
- AVG Volume (30 Days)
- HFRO 421.7K
- ALDX 311.8K
- Earning Date
- HFRO 01-01-0001
- ALDX 03-06-2025
- Dividend Yield
- HFRO 12.00%
- ALDX N/A
- EPS Growth
- HFRO N/A
- ALDX N/A
- EPS
- HFRO 1.23
- ALDX N/A
- Revenue
- HFRO $44,535,929.00
- ALDX N/A
- Revenue This Year
- HFRO N/A
- ALDX N/A
- Revenue Next Year
- HFRO N/A
- ALDX N/A
- P/E Ratio
- HFRO $5.50
- ALDX N/A
- Revenue Growth
- HFRO N/A
- ALDX N/A
- 52 Week Low
- HFRO $5.92
- ALDX $2.71
- 52 Week High
- HFRO $9.38
- ALDX $6.55
- Technical
- Relative Strength Index (RSI)
- HFRO 62.41
- ALDX 53.69
- Support Level
- HFRO $5.54
- ALDX $5.03
- Resistance Level
- HFRO $5.69
- ALDX $5.59
- Average True Range (ATR)
- HFRO 0.10
- ALDX 0.24
- MACD
- HFRO 0.02
- ALDX 0.03
- Stochastic Oscillator
- HFRO 93.45
- ALDX 54.44
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.